2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: A potential treatment for breast and prostate cancer

British Journal of Cancer

Volumn 99, Issue 11, 2008, Pages 1842-1848

  Tagg, S L C ^a   Foster, P A ^a   Leese, M P ^b   Potter, B V L ^b   Reed, M J ^a   Purohit, A ^a   Newman, S P ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

2 deoxy D glucose; 2 methoxyoestradiol 3,17 O,O bis sulphamate; Breast; Microtubule; Prostate

Indexed keywords

2 METHOXYPESTRADIOL 3,17 O,O BIS SULPHAMATE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; DEOXYGLUCOSE; STX 140; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYGLUCOSE; ESTRENES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 56749161667     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604752     Document Type: Article

References (27)

1. Aft RL, Zhang FW, Gius D (2002) Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer 87: 805-812
2. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumours: opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416
3. Chander SK, Foster PA, Leese MP, Newman SP, Potter BVL, Purohit A, Reed MJ (2007) In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyestradiol. Br J Cancer 96: 1368-1376
4. Day JM, Newman SP, Comninos A, Solomon C, Purohit A, Leese MP, Potter BVL, Reed MJ (2003) The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. J Steroid Biochem Mol Biol 84: 317-325
5. Fojo AT, Menefee M (2005) Microtubule targeting agents: basic mechanisms of multidrug-resistance (MDR). Semin Oncol 32: S3-S8
6. Foster PA, Ho YT, Newman SP, Kasprzyk PG, Leese MP, Potter BVL, Reed MJ, Purohit A (2008a) 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res Treat 111: 251-260
7. Foster PA, Newman SP, Leese MP, Bernetiere S, Diolez C, Camara J, Hacher B, Baronnet MM, Ali T, Potter BVL, Reed MJ, Purohit A (2008b) A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer. Anticancer Res 28: 577-581
8. Foster PA, Stengel C, Ali T, Leese MP, Potter BVL, Reed MJ, Purohit A, Newman SP (2008c) A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anticancer Res 28: 1483-1491
9. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP dependent transporters. Nature 2: 48-58
10. Gupta S, Mathur R, Dwarakanath BS (2005) The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumour-bearing mice. Cancer Biol Ther 4: 87-94
11. Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D, Leese MP, Smith AC, Potter BVL, Reed MJ (2004) Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 90: 932-937
12. Kaplan O, Navon G, Lyon RC, Faustino PJ, Straka EJ, Cohen JS (1990) Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res 50: 544-551
13. Lampidis TJ, Kurtoglu M, Maher JC, Liu H, Krishan A, Sheft V, Szymanski S, Fokt I, Rudnicki WR, Ginalski K, Lesyng B, Priebe W (2006) Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing 'hypoxic tumour cells'. Cancer Chemother Pharmacol 58: 725-734
14. Landau BR, Laszlo J, Stengle J, Burk D (1958) Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D- glucose. J Natl Cancer Inst 21: 485-494
15. Ledoux S, Yang R, Friedlander G, Laouari D (2003) Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res 63: 7284-7290
16. Leese MP, Leblond B, Smith A, Newman SP, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BVL (2006) 2-Substituted estradiol bis-sulfamates, multitargeted antitumour agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem 49: 7683-7696
17. Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ (2001) Hypersensitization of tumour cells to glycolytic inhibitors. Biochemistry 40: 5542-5547
18. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ (2004) 2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64: 31-34
19. Newman SP, Foster PA, Ho YT, Day JM, Raobaikady B, Kasprzyk PG, Leese MP, Potter BVL, Reed MJ, Purohit A (2007) The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. Br J Cancer 97: 1673-1682
20. Newman SP, Foster PA, Stengel C, Day JM, Ho YT, Judde J-G, Lassalle M, Prevost G, Leese MP, Potter BVL, Reed MJ, Purohit A (2008) The orally bioavailable microtubule disruptor, STX140, is efficacious in vitro and in vivo in taxane resistant breast carcinoma cells. Clin Cancer Res 14: 597-606
21. Newman SP, Leese MP, Purohit A, James DR, Rennie CE, Potter BVL, Reed MJ (2004) Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int J Cancer 109: 533-540
22. Nirenberg MW, Hogg JF (1958) Inhibition of anaerobic glycolysis in Ehrlich ascites tumour cells by 2-deoxy-D-glucose. Cancer Res 18: 518-521
23. Raobaikady B, Reed MJ, Leese MP, Potter BVL, Purohit A (2005) Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2 substituted oestradiol mono- and bis-3-O-sulphamates. Int J Cancer 117: 150-159
24. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR (2007) 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 67: 3364-3370
25. Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, Ravindranath T, Jain V (2005) Optimizing cancer radiotherapy with 2-deoxy-D-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 181: 507-514
26. Wachsberger PR, Gressen EL, Bhala A, Bobyock SB, Storck C, Coss RA, Berd D, Leeper DB (2002) Variability in glucose transporter-1 levels and hexokinase activity in human melanoma. Melanoma Res 12: 35-43
27. Warburg OH, Dickens F, Berlin Kaiser Wilhelm-Institut f è ur Biologie (1930) The Metabolism of Tumours: Investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlem. Constable & Co, Ltd: London